- Home
- INSW vs DNLI Comparison
INSW vs DNLI Comparison
Compare INSW & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INSW
- DNLI
- Stock Information
- Founded
- INSW 1999
- DNLI 2013
- Country
- INSW United States
- DNLI United States
- Employees
- INSW N/A
- DNLI N/A
- Industry
- INSW Semiconductors
- DNLI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- INSW Technology
- DNLI Health Care
- Exchange
- INSW Nasdaq
- DNLI Nasdaq
- Market Cap
- INSW 1.8B
- DNLI 2.1B
- IPO Year
- INSW N/A
- DNLI 2017
- Fundamental
- Price
- INSW $44.73
- DNLI $15.49
- Analyst Decision
- INSW Buy
- DNLI Strong Buy
- Analyst Count
- INSW 2
- DNLI 15
- Target Price
- INSW $52.00
- DNLI $33.62
- AVG Volume (30 Days)
- INSW 610.9K
- DNLI 1.8M
- Earning Date
- INSW 08-06-2025
- DNLI 08-11-2025
- Dividend Yield
- INSW 7.31%
- DNLI N/A
- EPS Growth
- INSW N/A
- DNLI N/A
- EPS
- INSW 4.81
- DNLI N/A
- Revenue
- INSW $798,838,000.00
- DNLI N/A
- Revenue This Year
- INSW N/A
- DNLI N/A
- Revenue Next Year
- INSW $1.88
- DNLI $323.34
- P/E Ratio
- INSW $9.30
- DNLI N/A
- Revenue Growth
- INSW N/A
- DNLI N/A
- 52 Week Low
- INSW $27.20
- DNLI $10.57
- 52 Week High
- INSW $54.84
- DNLI $33.33
- Technical
- Relative Strength Index (RSI)
- INSW 65.31
- DNLI 61.22
- Support Level
- INSW $41.21
- DNLI $14.15
- Resistance Level
- INSW $43.18
- DNLI $15.15
- Average True Range (ATR)
- INSW 1.52
- DNLI 0.75
- MACD
- INSW 0.12
- DNLI 0.15
- Stochastic Oscillator
- INSW 84.25
- DNLI 78.63
About INSW International Seaways Inc.
International Seaways Inc owns and operates a fleet of oceangoing vessels engaged in the transportation of crude oil and petroleum products. The company's vessel operations are organized into two segments: Crude Tankers and Product Carriers. The fleet consists of ULCC, VLCC, Suezmax, Aframax, and Panamax crude tankers, as well as LR1, LR2, and MR product carriers.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegeneration disease. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, DNL747, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others.